Status:
COMPLETED
Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis
Lead Sponsor:
Allergopharma GmbH & Co. KG
Conditions:
Birch Pollen Allergy
Eligibility:
All Genders
18-60 years
Phase:
PHASE3
Brief Summary
Safety and efficacy of recombinant birch pollen allergen in the treatment of allergic rhinoconjunctivitis
Eligibility Criteria
Inclusion
- Positive Skin Prick Test reaction to birch pollen
- Positive RAST result to birch pollen
- Positive Provocation Test result to birch pollen
Exclusion
- Serious chronic diseases
- Other perennial allergies
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
End Date :
June 1 2009
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00309062
Start Date
December 1 2003
End Date
June 1 2009
Last Update
March 11 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Allergopharma GmbH & Co. KG
Reinbek, Germany, 21465